Henlius Biotech tests appetite for HK IPO
Shanghai Henlius Biotech, which is being spun off by Shanghai Fosun Pharmaceutical (Group) Co, started gauging investor interest for its Hong Kong IPO on Monday, despite a choppy market.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: